Full-length hepatitis B virus sequences from naïve patients with fluctuation of viral load during ADV monotherapy

Virus Genes

Volumn 40, Issue 2, 2010, Pages 155-162

  Li, Yongwei ^a   Zhu, Mingfen ^b   Guo, Yunwei ^a   Chen, Wei ^a   Li, Gang ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Adefovir; Drug resistance; Full length genome; Hepatitis B virus

Indexed keywords

ADEFOVIR DIPIVOXIL; DNA POLYMERASE; EPITOPE; VIRUS DNA; VIRUS ENZYME; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; VIRUS PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHINA; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DNA DETERMINATION; DRUG EFFICACY; FEMALE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENETIC CONSERVATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MOLECULAR CLONING; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROMOTER REGION; VIRUS GENE; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; BLOOD; CHEMISTRY; DNA SEQUENCE; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MISSENSE MUTATION; TREATMENT FAILURE; VIROLOGY;

HEPATITIS B VIRUS;

ADENINE; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; FEMALE; GENOME, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHONIC ACIDS; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; TREATMENT FAILURE; VIRAL LOAD; VIRAL PROTEINS; YOUNG ADULT;

EID: 77951239233     PISSN: 09208569     EISSN: 1572994X     Source Type: Journal    
DOI: 10.1007/s11262-009-0429-z     Document Type: Article

References (34)

1. A.S.F. Lok, B.J. McMahon, AASLD practice guidelines. Hepatology 50(3):1-36 (2009)
2. W.F. Leemans, M.J. Ter Borg, R.A. de Man, Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment. Pharmacol. Ther. 26(Suppl 2), 171-182 (2007)
3. http://www.seqvirology.com/drugresistance.html
4. J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote et al., Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 352, 2673-2681 (2005)
5. H. Yang, C.E. Westland, W.E. Delaney IV, Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36, 464-473 (2002)
6. O. Schildgen, M. Helm, W. Gerlich, Nonresponse to adefovir: host or virus dependent. J. Clin. Virol. 37, 327-328 (2006)
7. C. He'zode, S. Chevaliez, M. Bouvier-Alias et al., Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine- resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. J. Hepatol. 46, 791-796 (2007)
8. M.D. Zeng, Y.M. Mao, G.B. Yao et al., A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 44(1), 108-116 (2006)
9. H.L. Chan, V.W. Wong, C.H. Tse et al., Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment. Pharmacol. Ther. 25, 891-898 (2007)
10. S. Locarnini, Molecular virology and the development of resistant mutants: implications for therapy. Semin. Liver Dis. 25(Suppl 1), 9-19 (2005)
11. S. Durantel, B. Werle, D. Durantel et al., Different profiles of response to adefovir dipivoxil, factors that may influence response in patients with chronic Hepatitis B. Hepatology 40, 654A (2004)
12. C.J. Oon, W.N. Chen, N. Lim et al., Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res. 41(3), 113-118 (1999)
13. S. Beckebaum, M. Malagó, O. Dirsch et al., Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin. Transplant. 17(6), 554-559 (2003)
14. W.S. Ayoub, E.B. Keeffe, Review article: current antiviral therapy of chronic hepatitis B. Aliment. Pharmacol. Ther. 28(2), 167-177 (2008)
15. A.S.F. Lok, B.J. McMahon, AASLD practice guidelines chronic hepatitis B. Hepatology 45(2), 507-539 (2007)
16. S. Günther, B.C. Li, S. Miska, A novel method for efficient amplification of whole hepatitis B virus genome permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J. Virol. 69, 5437-5444 (1995)
17. L.J. Stuyver, S.A. Locarnini, A. Lok et al., Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33(3), 751-757 (2001)
18. B. Werle, K. Cinquin, P. Marcellin, Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J. Viral Hepat. 11, 74-83 (2004)
19. M. Ghany, T.J. Liang, Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 132, 1574-1585 (2007)
20. C. Boni, A. Penna, G.S. Ogg et al., Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33, 963-971 (2001)
21. P.C. Tai, D. Bank, G.I. Lin et al., Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J. Virol. 71(6), 4852-4856 (1997)
22. W.N. Chen, J.O. Chong, Mutation "Hot Spot" in HLA class I-restricted T cell epitope on hepatitis B surface antigen in chronic carriers and hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 262, 757-761 (1999)
23. S.C. Mu, Y.M. Lin, G.-M. Jow, Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J. Hepatol. 50, 264-272 (2009)
24. C. Ferrari, A. Bertoletti, A. Penna et al., Identification of immunodominant T cell epitopes of the hepatitis virus nucleocapcid antigen. J. Clin. Invest. 88, 214-222 (1991)
25. E. Mizukoshi, J. Sidney, B. Livingston et al., Cellular immune responses to the hepatitis B virus polymerase. J. Immunol. 173, 5863-5871 (2004)
26. Y.K. Hwang, N.K. Kim, J.M. Park, HLA-A2.1 restricted peptides from the HBx antigen induce specific CTL responses in vitro and in vivo. Vaccine 20, 3770-3777 (2002)
27. C. Boni, P. Fisicaro, C. Valdatta et al., Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81, 4215-4225 (2007)
28. C.J. Liu, P.J. Chen, M.Y. Lai et al., Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34, 583-589 (2001)
29. J.L. Hou, Z.H. Wang, J.J. Cheng et al., Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology 34(5), 1027-1034 (2001)
30. S.Y. Lee, M.S. Choi, D. Lee et al., Overlapping gene mutations of hepatitis B virus in a chronic hepatitis B patient with hepatitis B surface antigen loss during lamivudine therapy. J. Korean Med. Sci. 20(3), 433-437 (2005)
31. P. Jain, DNA-guided hepatitis B treatment: viral load is insufficient with few exceptions. World J. Gastroenterol. 15(12), 1530-1531 (2009)
32. S. Amini-Bavil-Olyaee, J. Sheldon, T. Lutz et al., Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. AIDS 23(2), 268-272 (2009)
33. I. Chemin, F. Zoulim, Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett. 286, 52-59 (2009) (http://www.science direct.com/science).
34. C. Hannoun, K. Krogsgaard, P. Horal et al., Genotype mixtures of hepatitis B virus in patients treated with interferon. J. Infect. Dis. 186, 752-759 (2002)